This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-08-3260v1 69/11/4577    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Paternot, S. Articles by Roger, P. P. PubMed PubMed Citation Articles by Paternot, S. Articles by Roger, P. P.

Combined Inhibition of MEK and Mammalian Target of Rapamycin Abolishes Phosphorylation of Cyclin-Dependent Kinase 4 in Glioblastoma Cell Lines and Prevents Their Proliferation

Institute of Interdisciplinary Research, Université Libre de Bruxelles, Campus Erasme, Brussels, Belgium

Requests for reprints: Pierre P. Roger, Institute of Interdisciplinary Research, Université Libre de Bruxelles, Campus Erasme, 808 route de Lennik, B-1070 Brussels, Belgium. Phone: 32-2-555-41-53; Fax: 32-2-555-46-55; E-mail: proger{at}ulb.ac.be.

Key Words: rapamycin • PD184352 • CDK4 • CDK-activating kinase • D-type cyclins

The Ras/Raf/MEK/extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) signaling pathways are aberrantly activated in many tumors, including highly proliferative glioblastomas, but how they are wired with the cell cycle remains imperfectly understood. Inhibitors of MEK/ERK and mTOR pathways are tested as anticancer agents. They are generally considered to induce a G₁ cell cycle arrest through down-regulation of D-type cyclins and up-regulation of p27^kip1. Here, we examined the effect of targeting mTOR by rapamycin and/or MEK by PD184352 in human glioblastoma cell lines. In combination, these drugs cooperatively and potently inhibited the G₁-S transition and retinoblastoma protein phosphorylation. Their cooperation could not be explained by their partial and differential inhibitory effects on cyclin D1 or D3 but instead by their synergistic inhibition of the activating T172 phosphorylation of cyclin-dependent kinase (CDK) 4. This appeared independent of p27 and unrelated to weak modulations of the CDK-activating kinase activity. The T172 phosphorylation of CDK4 thus appears as a crucial node integrating the activity of both MEK/ERK and mTOR pathways. Combined inhibition of both pathways should be considered as a promising strategy for treatment of tumors harboring a deregulated CDK4 activity. [Cancer Res 2009;69(11):4577–81]

This article has been cited by other articles:

				L. Bockstaele, X. Bisteau, S. Paternot, and P. P. Roger Differential Regulation of Cyclin-Dependent Kinase 4 (CDK4) and CDK6, Evidence that CDK4 Might Not Be Activated by CDK7, and Design of a CDK6 Activating Mutation Mol. Cell. Biol., August 1, 2009; 29(15): 4188 - 4200. [Abstract] [Full Text] [PDF]